Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.46 |
| ▸ | F2R | P25116 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4513407 | 0.98 | ITGB3 (0.45) | ITGB3ITGA2BF2REPHX2EPHX1 | |
| SCHEMBL7227535 | 0.89 | ITGB3 (0.55) | ITGB3ITGA2BEPHX2EPHX1GNAI3 | |
| SCHEMBL7234515 | 0.87 | ITGB3 (0.57) | ITGB3ITGA2BEPHX2EPHX1GNAI3 | |
| SCHEMBL13804037 | 0.86 | ALDH1A1 (0.42) | EPHX2EPHX1GNAI3GNAO1GNAI1 | |
| SCHEMBL4599331 | 0.84 | ITGB3 (0.49) | ITGB3ITGA2BF2RGNAI3GNAO1 | |
| SCHEMBL3123567 | 0.83 | TPSAB1 (0.40) | EPHX2EPHX1GNAI3GNAO1GNAI1 | |
| SCHEMBL4505234 | 0.83 | EPHX2 (0.42) | EPHX2EPHX1GNAI3GNAO1GNAI1 | |
| SCHEMBL29223350 | 0.81 | ITGB3 (0.44) | ITGB3ITGA2BF2RGNAI3GNAO1 | |
| SCHEMBL30684623 | 0.81 | ITGB3 (0.46) | ITGB3ITGA2BF2RGNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL5981760 | 0.80 | EPHX2 (0.40) | EPHX2EPHX1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1319661-B1 | PROCESS FOR PRODUCING A TRICYCLIC FUSED HETEROCYCLIC DERIVATIVE | TAKEDA PHARMACEUTICAL (JP) | 2006-03-01 | — | — | EP | claimed |
| US-6881842-B2 | Process for producing tricyclic fused heterocyclic derivative | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-04-19 | — | — | US | claimed |
| US-20030191150-A1 | Process for producing tricyclic fused heterocyclic derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-09 | — | — | US | claimed |
| EP-1319661-A1 | PROCESS FOR PRODUCING TRICYCLIC FUSED HETEROCYCLIC DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2003-06-18 | — | — | EP | claimed |
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-10662199-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2701699-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-9890172-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20180016282-A9 | INHIBITORS OF HISTONE DEACETYLASE | HOWARD HUGHES MEDICAL INSTITUTE | 2018-01-18 | — | — | US | disclosed |
| US-20170217955-A9 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-20160347761-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2016-12-01 | — | — | US | disclosed |
| EP-0607864-A2 | Tricyclic condensed heterocyclic compounds for the treatment of senile dementic | Takeda Chemical Industries, Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
| EP-0602242-A1 | BENZISOXAZOLE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| US-5294625-A | 1-benzyl,4-((4-dialkylaminophenyl)carbonyl)piperidines | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-03-15 | — | — | US | disclosed |
| US-5273974-A | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| EP-0378207-B1 | CYCLIC AMINE COMPOUNDS AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 1993-09-22 | — | — | EP | disclosed |
| US-5177087-A | Cerebral edema, cholinesterase inhibitor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| EP-0487071-A1 | Condensed heterocyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-05-27 | — | — | EP | disclosed |
| EP-0378207-A1 | Cyclic amine compounds and their use | Takeda Chemical Industries, Ltd. (JP) | 1990-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347761-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC11 | ITGB3 3686/4885ITGA2B 1196/4885F2R 781/4885 |
| US-10662199-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | ITGB3 3686/4885ITGA2B 1196/4885F2R 781/4885 |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC11 | ITGB3 3686/4885ITGA2B 1196/4885F2R 781/4885 |
| US-11572368-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | ITGB3 3686/4885ITGA2B 1196/4885F2R 781/4885 |
| US-20030191150-A1 | Process for producing tricyclic fused heterocyclic derivative | ACHE, BCHE, COASY | ITGB3 4747/4885ITGA2B 4588/4885F2R 1821/4885 |
| US-20170217955-A9 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC11 | ITGB3 3824/4885ITGA2B 1544/4885F2R 797/4885 |
| US-20180016282-A9 | INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC11 | ITGB3 3686/4885ITGA2B 1196/4885F2R 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.